TearLab Corporation TEAR announced today that it is in receipt
of a communication from the U.S. Food and Drug Administration
indicating that, based on a supervisory review of the Company's appeal, the
Agency has granted its petition for a waiver under CLlA for the TearLab
Osmolarity System. Upon the Company's submission of labeling acceptable to the
Agency, the CLIA waiver will be issued.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in